Omeros Valuation Multiples

Omeros Overview

About Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Founded

1994

HQ

Employees

202

Website

omeros.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $33M

Net Income: ($1M)

EV

$924M

Valuation Multiples

Multiples.vc

Start free trial

Omeros Financials

Omeros reported last 12-month revenue of $33M.

In the same LTM period, Omeros generated $32M in gross profit and had net loss of ($1M).

Omeros P&L

In the most recent fiscal year, Omeros reported revenue of — and EBITDA of ($122M).

Omeros expects next 12-month revenue of XXX and NTM EBITDA of XXX

Omeros Stock Performance

Omeros has current market cap of $857M, and enterprise value of $924M.

Omeros' stock price is $11.90.

Omeros Valuation Multiples

Omeros trades at 27.9x EV/Revenue multiple, and (7.6x) EV/EBITDA.

Omeros Financial Valuation Multiples

As of April 11, 2026, Omeros has market cap of $857M and EV of $924M.

Equity research analysts estimate Omeros' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Omeros has a P/E ratio of (747.4x).

Omeros Margins & Growth Rates

Omeros' revenue in the last 12 month grew by 374%.

Omeros' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.

Omeros Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Omeros M&A Activity

Omeros acquired XXX companies to date.

Last acquisition by Omeros was on XXXXXXXX, XXXXX. Omeros acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Omeros Investment Activity

Omeros invested in XXX companies to date.

Omeros made its latest investment on XXXXXXXX, XXXXX. Omeros invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).